#535 Roxadustat as a treatment of anemia after kidney transplantation

作者
Monika Beliančinová,Tímea Blichová,Patrícia Kleinová,Karol Graňák,Matej Vnučák,Ivana Dedinská
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
卷期号:39 (Supplement_1)
标识
DOI:10.1093/ndt/gfae069.992
摘要

Abstract Background and Aims Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favourable safety and efficacy in the treatment of renal anaemia. The goal of this study is to analyse the effect of roxadustat on the level of hemoglobin in a group of patient with chronic kidney disease with or without kidney transplantation. Method This is a monocentric study conducted on the patients of Transplant-nephrology department and/or Transplant-nephrology out-patient clinic of University Hospital Martin, Slovakia who have been treated with roxadusat since August 1st, 2022. Results 33 patients were included in the study. The average follow up of treatment with roxadustat was 4.2 months. The following parameters were recorded at the baseline: age, gender, estimated glomerular filtration rate—eGFR (CKD-EPI), treatment with iron and level of iron in serum, level of C-reactive protein, level of hemoglobin, starting dose of Roxadustat. We discovered a significant improvement in the levels of hemoglobin after one month of roxadustat treatment (P < 0.0001) and another significant improvement in follow-up (P ‚0,0373). There was no significant difference in eGFR, CRP or iron levels during follow up, so hemoglobin levels were not affected by inflammation or kidney function. In the next step the group of patients was divided based on history of kidney transplantation. Again, we confirmed significant improvement in hemoglobin levels in kidney transplantation group in first month of treatment (P < 0.0001) as well as in follow up (P < 0.0001). There was a significant improvement in hemoglobin levels in the first month of roxadustat treatment in the group of patients who did not undergo kidney transplantation (P = 0.0261). However, there was no significant difference between hemoglobin levels in month 1 and follow up in this group. Conclusion Roxadustat—as a new treatment option of anaemia for patients with chronic kidney diseases. Our first analysis confirmed that roxadustat is very effective not only in patients with CKD, but also in patients with anaemia after kidney transplantation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JQ完成签到,获得积分10
1秒前
cyh完成签到,获得积分10
1秒前
1秒前
哒哒就是我完成签到,获得积分10
1秒前
大虫完成签到,获得积分10
1秒前
ryy发布了新的文献求助10
2秒前
3秒前
陈砍砍完成签到 ,获得积分10
3秒前
lulululu完成签到,获得积分10
3秒前
大模型的应助被刘sss采纳,获得10
3秒前
GUO完成签到,获得积分10
3秒前
JQ发布了新的文献求助10
3秒前
科研通AI6.4的应助被奥特曼采纳,获得10
3秒前
不知道起个什么名字完成签到 ,获得积分10
3秒前
mengyi完成签到 ,获得积分10
4秒前
4秒前
4秒前
4秒前
1111111111关注了科研通微信公众号
4秒前
4秒前
4秒前
4秒前
氵漏漏完成签到,获得积分10
4秒前
万能图书馆的应助被天真依白采纳,获得10
5秒前
科研通AI6.4的应助被AL采纳,获得10
5秒前
情怀的应助被蜂情蜜恋采纳,获得10
5秒前
赘婿的应助被清爽念烟采纳,获得10
5秒前
insist完成签到,获得积分20
5秒前
CodeCraft的应助被chenwudu采纳,获得10
5秒前
科研通AI2S的应助被一一采纳,获得10
5秒前
乘风完成签到,获得积分10
5秒前
Amos发布了新的文献求助10
6秒前
拜拜碳酸完成签到,获得积分10
6秒前
丘比特的应助被dandelionshun采纳,获得10
6秒前
无极微光的应助被liuliumei采纳,获得20
6秒前
hhzhangf完成签到,获得积分10
7秒前
7秒前
orixero的应助被温婉的如波采纳,获得10
8秒前
9秒前
小陈发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180927
求助须知:如何正确求助?哪些是违规求助? 9570973
关于积分的说明 21815578
捐赠科研通 7777227
什么是DOI,文献DOI怎么找? 3433367
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479346